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BACKGROUND: Endometriosis is considered a frequent, benign disease with the ability to undergo neoplastic
processes. The aim of this study was to evaluate the limitless replication potential of the endometrium in patients with
endometriosis by examining human telomerase reverse transcriptase (hTERT) mRNA expression and telomerase
activity. METHODS: Endometrium samples from 30 endometriosis patients and 30 patients without endometriosis
were obtained via endometrial biopsy. The expression of hTERT mRNA was determined by real-time RT–PCR
assay, and telomerase activity was measured by telomerase repeat amplification protocol (TRAP) assay. RESULTS:
The mean normalized hTERT (N hTERT) mRNA level was significantly higher in the endometriosis than in the con-
trol group (P = 0.013). The mean hTERT mRNA levels during the proliferative phase and during the secretory phase
were higher in the endometriosis group than in the control group, although the difference was only significant for the
secretory phase (P = 0.036). We found a prominent difference in endometrial telomerase activity between moderate-
to-severe endometriosis and the control group (P = 0.048). The levels of hTERT mRNA and telomerase activity
increased as the disease became more severe (P = 0.038, P = 0.016). CONCLUSIONS: This study showed the overex-
pression of hTERT mRNA and telomerase activity in the endometrium of endometriosis patients. These finding sug-
gest that replication potential of endometrial cells may have an important role in the pathogenesis of endometriosis.
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Introduction
Endometriosis is defined as an implantation of endometrial tis-
sues outside their normal location in the uterus. Overall,
endometriosis may affect 7–15% of women of reproductive
age and usually results in various symptoms such as chronic
pelvic pain, dysmenorrhoea and infertility (Lapp, 2000). In
infertile women, the prevalence may be as high as 30–40%,
and the incidence of this disease is increasing.
In 1927, the pelvic implantation theory by retrograde men-
struation of endometrial tissues was first described by Samp-
son (1927). It is the most widely accepted theory on the
pathogenesis of endometriosis. However, no single mechanism
can explain all cases of endometriosis, and the pathogenesis is
not yet fully understood. Recently, other familial predispositions,
immunological factors, cell adhesion factors, angiogenic fac-
tors and hormonal factors have been introduced (Wells,
2004). In fact, immunological factors may affect susceptibil-
ity to the implantation of endometrial cells, which are shed
from the endometrial cavity, and there is much evidence sup-
porting the hypothesis that endometriosis is inherited as a com-
plex genetic trait correlated with susceptibility (Berkkanoglu
and Arici, 2003; Kennedy, 2003).
Endometrium from endometriosis patients could have
endogenous abnormalities that predispose these patients to the
disease, and some genes or gene products are aberrantly
expressed in these tissues (Sharpe-Timms, 2001; Giudice and
Kao, 2004). Up-regulation of anti-apoptotic genes, such as bcl-2,
has been noted in the eutopic endometrium of women with
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endometriosis (Jones et al., 1998). Moreover, Kao et al. (2003)
have reported that dysregulation of some genes in endometrium
of women with endometriosis contributes to implantation failure
and infertility.
Although it would be inappropriate to define endometriosis as
a premalignant lesion, endometriosis is clinicopathologically
similar to neoplastic disease. Endometriosis undergoes malignant
transformation such as clear cell or endometrioid ovarian cancer.
Also, this disease shares a predisposing factor and molecular sim-
ilarity with cancer (Varma et al., 2004). Angiogenesis, tissue
invasion and metastasis are all found in endometriosis patients.
Similarly, endometriotic lesions have also displayed an overex-
pression of anti-apoptotic (bcl-2) genes and an underexpression
of pro-apoptotic (bax) genes (Meresman et al., 2000).
Telomeres are repetitive DNA sequences (5′-TTAGGG-3′),
at the ends of linear chromosomes, which shorten along with
cellular division in somatic cells. Telomerase is a ribonucleo-
protein complex and plays an important role in telomere main-
tenance and cellular immortality (Rhyu, 1995). Normal somatic
cells, except hematopoietic stem cells and endometrial cells, do
not usually express telomerase. However, telomerase activity
has been detected in various cancers and is related to limitless
replication potential. Human telomerase reverse transcriptase
(hTERT) is a core functional component of telomerase activity.
It is a catalytic protein subunit, and a strong correlation has
been observed between hTERT mRNA expression and telomer-
ase activity in various tissues (Oshita et al., 2000; Baykal et al.,
2004). It has been proven that hTERT mRNA is a critical deter-
minant of telomerase activity (Kyo et al., 1999). Endometrial
telomerase activity has been reported to be high during the pro-
liferative phase but is suppressed during the secretory phase of
the menstrual cycle. This finding reflects the relationship
between telomerase activity and features of the normal
endometrium, which is regularly regenerated and has prolifera-
tive potential (Yokoyama et al., 1998). Lehner et al. (2002)
reported that telomerase activity and hTERT mRNA levels are
significantly higher in endometrial cancer compared with that in
the normal, cycling endometrium.
However, no studies concerning telomerase activity in
endometriosis patients have been published. Endometriosis is
an estrogen-dependent disease with a process similar to that of
a neoplastic disease, therefore we hypothesise that increased
telomerase activity in the endometrium of endometriosis
patients may have a role in the pathogenesis of endometriosis.
In this study, we evaluated the limitless replication potential
of the endometrium in women with endometriosis by quantita-
tive examination of hTERT mRNA expression and telomerase
activity. Additionally, we analysed the relationship between
hTERT mRNA levels and telomerase activities.
Materials and methods
Patients and tissue selection
Fresh surgical specimens from 30 endometriosis patients and 30 nor-
mal control tissues were collected via endometrial biopsy. Biopsies
were performed during exploration laparotomy or operative laparos-
copy at the Department of Obstetrics and Gynecology, Yongdong
Severance Hospital, Yonsei University College of Medicine from
September 2005 to March 2006. Each sample was immediately frozen
and stored at –80°C until use. Ectopic endometrial tissues in the
endometriosis group were sent to the Pathology Department, and
endometriosis was histologically determined. Informed consent was
obtained from all patients, and the study was approved by the institu-
tional review board.
Post-menopausal women, previous hormone or GnRH agonist users
and patients who had adenomyosis, endometrial cancer, endometrial
hyperplasia or endometrial polyps were excluded.
The endometriosis and control groups were then divided and ana-
lysed according to menstrual phases and clinical disease stages estab-
lished by the revised classification of The American Society for
Reproductive Medicine (1997). Endometrial dating was determined
from the histology of the endometrium (Noyes et al., 1950) and clas-
sified into seven phases of the menstrual cycle (menstrual, early-,
mid-, late-proliferative and early-, mid-, late-secretory phase). Of 60
women, 8 women were in the early-proliferative phase, 9 were in the
mid-proliferative phase, 9 were in the late-proliferative phase, 10 were
in the early-secretory phase, 12 were in the mid-secretory and 12 were
in the late-secretory phase of their menstrual cycles. Of the 30 women
with endometriosis, 13 were in the proliferative phase (3 in the early-,
5 in the mid- and 5 in the late-proliferative phase) and 17 were in the
secretory phase (4 in the early-, 7 in the mid- and 6 in the late-secretory
phase). Of the 30 control women, 13 were in the proliferative
phase (5 in the early-, 4 in the mid- and 4 in the late-proliferative
phase) and 17 were in the secretory phase (6 in the early-, 5 in the
mid- and 6 in the late-secretory phase). Of the 30 women with
endometriosis, 4 were classified as endometriosis stage I, 4 as
endometriosis stage II, 11 as endometriosis stage III and 11 as
endometriosis stage IV.
Quantification of human hTERT mRNA
Total RNA was isolated from biopsied tissue, using the RNeasy Mini
Kit (QIAGEN, Valencia, CA, USA) and following the protocol sug-
gested by the manufacturer. Total RNA (2 μg) was reverse transcribed
into cDNA, using the SuperScript™ III first-strand synthesis system
(Invitrogen, Carlsbad, CA, USA). Two micrograms of total RNA was
mixed with 1 μl Oligo(dT)20 primer (0.5 μg/μl), 1 μl dNTPs and deion-
ized water. The total volume of 10 μl was incubated at 65°C for 5 min.
After mixing with 2 μl of 10× reverse transcriptase (RT) buffer,
25 mM MgCl2 (4 μl), 0.1 M dithiothreitol (DTT) (2 μl), recombinant
RNase inhibitor (RNase OUT TM) (400 U/μl, 1 μl) and SuperScript™
III RT (200 U/μl, 1 μl), each sample was placed in a thermal cycler at
50°C for 50 min; the cycle was stopped at 85°C for 5 min.
The expression of hTERT mRNA was measured by real-time
RT–PCR, based on the TaqMan methodology, using a LightCycler®
instrument (Roche Diagnostics, Mannheim, Germany). The spe-
cific primers and probe nucleotide sequence for hTERT were for-
ward primer 5′-TGACACCTCACCTCACCCAC-3′, reverse primer
5′-CACTGTCTTCCGCAAGTTCAC-3′ and TaqMan probe
5′-(FAM)ACCCTGGTCCGAGGTGTGTCCCTGA(TAMRA)-3. The
primers and probe for glyceraldehyde-3-phosphatedehydrogenase
(GAPDH) were forward primer 5′-GAAGGTGAAGGTCGGAGTC-3′,
reverse primer 5′-GAAGATGGTGATGGGATTTC-3′ and TaqMan
probe 5′-(FAM)CAAGCTTCCCGTTCTCAGCC(Tamra)-3′.
For each PCR run, a master mix was prepared on ice with Taq
polymerase buffer, 4 mmol/l MgCl2, 200 μmol/l deoxynucleotides,
300 nmol/l each primer, 150 nmol/l probe, 1 U Taq polymerase and
20 ng cDNA. PCR was performed in a total volume of 20 μl. The ther-
mal cycling conditions included pre-incubation for 10 min at 95°C, fol-
lowed by 40 cycles of 10 s at 95°C, 30 s at 63°C and 1 s at 72°C.
To normalize the amount of total RNA present in each reaction, we
amplified the housekeeping gene GAPDH. Our final result was
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expressed as a normalized hTERT (N hTERT) mRNA. The amount of
target, which was normalized to the endogenous reference (GAPDH)
and was compared to the calibrator, was defined by the ΔΔCt method.
The normalization formula is target amount = 2–ΔΔCt, where ΔΔCt =
{[Ct(hTERT sample) – Ct (GAPDH sample)] – [Ct (hTERT calibra-
tor) – Ct (GAPDH calibrator)]}, which was calculated by LightCycler
software version 4.0.
Telomerase activity
Telomerase activity was determined according to the telomerase
repeat amplification protocol (TRAP) assay that was first described by
Kim et al. (1994).
Endometrial tissue samples were washed with phosphate-buffered
saline (PBS) and then suspended in lysis buffer. Tissues were then
homogenized and incubated on ice for 30 min. Cell homogenates
were then centrifuged at 14 000 × g for 30 min at 4°C. A supernatant
160 μl was recovered, and the protein concentration was measured
using a BCA assay kit (Sigma-Aldrich, St. Louis, MO, USA).
The SYBR Green real-time quantitative TRAP assay was conducted
with a Quantitative Telomerase Detection kit (EBI, Frederick, MD,
USA). The total volume of the reaction mixture was 25 μl, which con-
tained 12.5 μl of quantitative telomerase detection (QTD) premix,
11.5 μl of PCR qualified water and 1.0 μl of tissue extract. About
0.01 μg of protein extract was used for the TRAP assay. The reaction
mixture was first incubated at 25°C for 20 min to allow the telomerase
in the protein extracts to elongate the TS primer (5′-AATCCGTC-
GAGCAGAGTT-3′) by adding a TTAGGG-repeat sequence. After
that, PCR was then performed at 95°C for 10 min followed by 45
cycles of amplification at 95°C for 30 s, 60°C for 30 s and 72°C for
30 s on a MiniOpticon real-time PCR machine (Bio-Rad, Hercules,
CA, USA). The amplified fluorescence signal in each specimen was
measured at the late extension step of each cycle and analysed with
Detector software. In the negative control, no fluorescent signal was
observed. A standard curve was generated from serial dilutions of tel-
omerase-positive telomerase substrate oligonucleotide (TSR) template
(0.5, 0.1, 0.02, 0.004, 0.008, 0.00016, 0.000032 and 0.0000064 μg/ml).
The telomerase activity of each specimen was calculated based on the
standard curve. One unit of relative telomerase activity (RTA) was
defined as the activity equivalent to that in 100 molecules of TSR.
Statistical analysis
Comparison of values between the endometriosis and control groups
was done using the Student’s t-test. The levels of significance in cor-
relation were calculated by Pearson’s correlation coefficient. Analysis
according to the clinical disease stages in the endometriosis group was
done using the Kruskall–Wallis test, because a normal distribution
was not obtained. All tests were performed with SPSS version 13.0
software (SPSS Inc., Chicago, IL, USA), and a P value <0.05 was
considered statistically significant.
Results
Clinical features
A total of 30 samples from each group were examined. The
mean age of the endometriosis group was 32.7 ± 6.8 years
(mean ± SD) and that of normal control group was 34.6 ± 6.7
years (P = 0.254). The body mass index (BMI) and haemo-
globin level of each group were not significantly different. The
level of serum CA 125 in the endometriosis group (56.5 ±
39.9) was significantly higher than in the control group (20.2 ±
10.5) (Table I).
Expression of hTERT mRNA
hTERT mRNA expression was detected in 27 of 30 (90%)
specimens from the endometriosis group and in 24 of 30 (80%)
samples from the normal control group. The mean level of N
hTERT mRNA was significantly higher in the endometriosis
group than in the control group (52.4 ± 53.7 versus 22.4 ± 24.2,
P = 0.013) (Table II).
When hTERT mRNA expression of endometrial tissue was
analysed according to different phases in all subjects irrespec-
tive of disease status, late-proliferative phase showed the max-
imum expression and the late-secretory phase showed the
minimum expression. Nine subjects without expression were
all from the late-secretory phase (Figure 1A).
When comparing hTERT mRNA expression according to
menstrual phase, the hTERT mRNA levels were highest in the
proliferative phase of the endometriosis group and lowest in
the secretory phase of the control group (Figure 2A). In both
groups, the level of hTERT mRNA was higher in the prolifera-
tive phase than in the secretory phase, but no significant differ-
ences were found. Although the level of hTERT mRNA during
the proliferative was higher in the endometriosis group than in
the control group, the difference was also not significant. How-
ever, when the hTERT mRNA level during secretory phase in
the control group was compared with that in the endometriosis
group, it was significantly higher in the latter (17.7 ± 25.1 versus
47.2 ± 40.1, P = 0.036).
According to the clinical disease stages in the endometriosis
group, hTERT mRNA expression increased by a statistically
significant level as the disease became more severe (P =
0.038). The mean N hTERT level in the endometriosis group
was 10.40 (range 8.85–11.96, median 10.40) in stage I, 16.78
(range 8.75–26.78, median 14.83) in stage II, 47.64 (range
6.07–140.35, median 25.35) in stage III and 74.62 (range
20.17–260.70, median 62.85) in stage IV (Figure 3A).
Table I. Clinical characteristics of the study groups
BMI, body mass index, Hb, haemoglobin.
Data are expressed as mean ± SD.
*P < 0.05.
Control 
(n = 30)
Endometriosis 
(n = 30)
P value
Age (year) 34.6 ± 6.7 32.7 ± 6.8 0.254
BMI (kg/m2) 22.0 ± 2.3 21.3 ± 2.2 0.240
Hb (g/dl) 12.3 ± 2.3 21.3 ± 2.2 0.785
Serum CA-125 (IU/ml) 20.2 ± 10.5 56.5 ± 39.9 <0.001*
Table II. Human telomerase reverse transcriptase (hTERT) mRNA 
expression in the study groups
N hTERT, normalized hTERT.
Data are expressed as mean ± SD.
*P < 0.05.
Control group Endometriosis group P value
Positive hTERT mRNA
expression (%)
24/30 (80%) 27/30 (90%)
N hTERT 22.4 ± 24.2 52.4 ± 53.7 0.013*
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Although slight positive correlation could be seen between
hTERT mRNA expression and the endometriotic cyst size in
the endometriosis group, there was no significant correlation
between the two variables (r = 0.349, P = 0.074). Finally,
when comparing the hTERT mRNA expression and the serum
CA 125 level, no significant correlation was found (r = 0.193,
P = 0.335).
Telomerase activity detection
Telomerase activity was found in 27 of 30 (90%) endometrio-
sis patients and in 27 of 30 (90%) normal patients. The level of
RTA was higher in the endometriosis than in the control group,
but no significant difference was noted. However, when only
the moderate-to-severe endometriosis group was compared
with the control group, the difference was statistically signific-
ant (21.8 ± 33.0 versus 7.6 ± 13.2, P = 0.048) (Table III).
Figure 1. Changes in human telomerase reverse transcriptase (hTERT)
mRNA expression and telomerase activity in endometrium of total
subjects during the different phases of the menstrual cycle. (A) Maximal
hTERT mRNA expression was noted in the late-proliferative
phase and minimal expression was noted in the late-secretory
phase. Nine subjects without expression were all in the late-secretory
phase. (B) Telomerase activity of endometrium was found to have a
similar pattern as hTERT mRNA expression. Six samples without
activity were all from the late-secretory phase. EP, early-proliferative
phase; ES, early-secretory phase; LP, late-proliferative phase; LS,
late-secretory phase; MP, mid-proliferative phase; MS, mid-secretory
phase. Black bar: mean value of the phase.
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Figure 2. Human telomerase reverse transcriptase (hTERT) mRNA
expression and telomerase activity in the study groups according to
menstrual phase. (A) The hTERT mRNA level during the secretory
phase in the control group was compared with the endometriosis
group and was found to be significantly higher in the latter (17.7 ±
25.1 versus 47.2 ± 40.1, P = 0.036). Although the hTERT mRNA
level during the proliferative phase was higher in the endometriosis
group than in the contriol group, the difference was not significant.
(B) Telomerase activity was higher during the proliferative phase than
during the secretory phase for each group and was higher in the
endometriosis group than in the control group during each phase, but
no significant differences were found. In both groups, all samples
without hTERT mRNA and telomerase activity were from the secre-
tory phase. (C) The expression pattern of glyceraldehyde-3-phosphat-
edehydrogenase (GAPDH) (lower) and hTERT mRNA (upper) in the
both groups by representative RT–PCR bands. Lanes 1, 5, prolifera-
tive phase of control group; lanes 2, 6, secretory phase of control
group; lanes 3, 7, proliferative phase of endometriosis group; and
lanes 4, 8, secretory phase of endometriosis group. *P < 0.05, N hTERT,
normalized hTERT mRNA.
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As shown in Figure 1B, telomerase activity was revealed
to have a pattern similar to the level of hTERT mRNA
expression when assessed according to menstrual phase. Six
samples without telomerase activity were all from the late-
secretory phase. In both the control and the endometriosis
groups, telomerase activity was higher in the proliferative
phase than in the secretory phase, but no significant differ-
ences were found. Also, when the control and endometriosis
groups in each menstrual phase were compared, telomerase
activity was higher in the latter, although the differences were
not significant (Figure 2B).
We analysed the level of RTA according to clinical dis-
ease stage in the endometriosis group and found a trend of
increasing telomerase activity with increasing stage of
endometriosis (Figure 3B). This result was similar to the
results of hTERT mRNA and was statistically significant
(P = 0.016).
There was no significant correlation between telomerase
activity and the size of the endometriotic cyst in the endometri-
osis group (r = 0.178, P=0.197). Moreover, when the level of
telomerase activity and serum CA 125 were compared, no sig-
nificant correlation was detected (r = 0.199, P = 0.219).
Correlation of hTERT mRNA and telomerase activity
We examined the relationship between hTERT mRNA expres-
sion by quantitative real-time RT–PCR and telomerase activity
by TRAP assay in all samples. A significant, positive correla-
tion was found, and the levels of hTERT mRNA and telomer-
ase activity showed a linear association (r = 0.778, P < 0.001)
(Figure 4).
Discussion
Endometriosis is characterized by the growth of endometrial
tissue outside the uterus, but the aetiology and the pathogenesis
of this disease remain unclear. Endometriosis tends to recur
and progress, and the cumulative recurrence rate is ∼40% after
5 years, regardless of medical or surgical treatment (Fedele
et al., 1994). Therefore, it is very important to determine the
pathogenesis of this disease.
Several studies have focused on the overexpressed genes in
the endometrium of endometriosis patients. Persistent expression
Figure 3. Comparison of human telomerase reverse transcriptase (hTERT) mRNA expression and telomerase activity between clinical disease
stages in the endometriosis group. (A) hTERT mRNA expression increased significantly as the disease became more severe (P = 0.038). (B) A
trend of increasing telomerase activity with increasing stage of endometriosis (P = 0.016) was observed. All samples without hTERT mRNA and
telomerase activity were those of minimal-to-mild disease (two cases in stage I and one case in stage II).
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Table III. Telomerase activity in the study groups
III–IV EMS, moderate-to-severe endometriosis.
Data are expressed as mean ± SD.
*P < 0.05.
Control group Endometriosis P value
Telomerase activity
expression(%)
27/30 (90%) 27/30 (90%) 0.122
7.6 ± 13.2 17.8 ± 30.8
Relative telomerase
activity (RTA) III–IV EMS (n = 22)
7.6 ± 13.2 21.8 ± 33.0 0.048*
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of matrix metalloproteinases (MMPs), abundant expression of
several angiogenic factors, including interleukins 1, 6 and 8,
and increased expression of fibroblast growth factors could
contribute to the establishment of endometriotic lesions in the
peritoneal cavity (Osteen et al., 1999; Taylor et al., 2002). Up-
regulation of anti-apoptotic genes and down-regulation of pro-
apoptotic genes have also been observed in the endometrium of
endometriosis patients (Harada et al., 2004). Likewise Giudice
and Kao (2004) reported that there is an intrinsic abnormality
in eutopic endometrium in women with endometriosis that per-
mits these tissues to attach, survive, invade and establish a
blood supply in the peritoneun.
In this study, we examined hTERT mRNA expression and
telomerase activity to evaluate the limitless replication poten-
tial of the endometrium in endometriosis patients. Higher lev-
els of both parameters were detected in endometriosis patients
when compared with the normal control group.
The hTERT mRNA was not expressed in 10% (3/30) of the
endometriosis group and 20% (6/30) of the control group.
These results are similar to previous studies, regarding hTERT
mRNA expression in normal endometrium (Kyo et al., 1999;
Lehner et al., 2002). All samples without expression were from
the late-secretory phase. Telomerase activity was not detected
in 10% of samples from both groups. This expression rate was
somewhat higher than that of other studies, because we used a
real-time TRAP assay instead of the conventional TRAP assay
(Shroyer et al., 1997; Maida et al., 2002). The conventional
TRAP assay requires complex post-amplification procedures,
such as polyacrylamide gel electrophoresis, autoradiography
and densitometry for measurement of telomerase products,
whereas a real-time TRAP assay reduces the risk of carryover
contamination and provides a more rapid and reliable quantifi-
cation of telomerase activity (Wege et al., 2003). The samples
without telomerase activity were all from the late-secretory
phase. Particularly, within the endometriosis group, all samples
without telomerase activity were those of minimal-to-mild
disease. There may be a number of reasons why the expression
was not detected in some women. First, telomerase activity
might have been below the threshold of detection of available
assay. Also, an alternative mechanism compensating for the
end-replication problem could have existed.
Our experiment demonstrated a significant difference in
hTERT mRNA levels between the two groups. However, when
the level of telomerase activity was compared, we found a
prominent difference only between moderate-to-severe
endometriosis patients and the control group. These results
reflect the presence of multiple mechanisms for regulating tel-
omerase activity. Post-transcriptional regulation of the hTERT
gene, such as alternative splicing of hTERT transcripts and
protein kinase C-mediated phosphorylation of hTERT, can
modulate the enzyme activity at multiple levels (Li et al., 1998;
Ulaner et al., 2000).
In this study, the patterns of hTERT mRNA and telomerase
activity, throughout the menstrual phase, were consistent with
a previous study (Kyo et al., 1999). This suggests that telomer-
ase activation is closely associated with cellular proliferative
activity and self-regeneration of the endometrium. In addition,
Belair et al. (1997) reported that telomerase activity is a
biomarker of cell proliferation, rather than that of malignant
transformation. Estrogen may play a role in the regulation of
telomerase activity as a potent inducer of endometrial prolifer-
ation. Telomerase expression, in fact, declines rapidly after
ovulation when the estrogen level decreases. Furthermore, it is
suppressed by progesterone (Williams et al., 2001). The inter-
esting feature of this study was that the hTERT mRNA level
during both the proliferative and secretory phases is higher in
the endometriosis group when compared with that in the con-
trol group, although the difference was only significant for the
secretory phase. This may indicate that the tissue from
endometriosis is different from normal endometrium, which
undergoes estrogen-induced cell proliferation that is sup-
pressed by progesterone.
We found that hTERT mRNA expression and telomerase
activity were significantly different according to the different
stages of endometriosis. This finding suggests that hTERT
mRNA expression and telomerase activity may reflect the
severity of the disease. However, we had a small number of
samples with the minimal-to-mild disease. Therefore, further
studies with a large number of cases are needed to confirm this
result.
This study revealed that there was a statistically significant
association between hTERT mRNA level and telomerase
activity in both groups. However, we found discordant results
in some cases: a few patients had relatively high telomerase
activity with a low hTERT mRNA level, whereas some cases
demonstrated the inverse association. The former may result
from inefficient RNA extraction or RNA degradation in the
clinical samples, whereas the latter may reflect suboptimal
extraction of telomerase or enzyme instability. In addition,
other mechanisms, such as post-transcriptional regulation, may
play an important role in telomerase activity.
In conclusion, our results represent the first evidence
that telomerase activity and hTERT mRNA expression are
Figure 4. Correlation between human telomerase reverse tran-
scriptase (hTERT) mRNA expression and telomerase activity. A sig-
nificant, positive correlation was found, and the level of hTERT
mRNA and telomerase activity showed a linear association (r = 0.778,
P < 0.001).
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correlated with the proliferative potential of the endometrium
in endometriosis patients. In addition, we suggest that the
replication potential of regurgitated endometrial tissue in the
peritoneal cavity is crucial for the development of viable
implants and may have an important role in the pathogenesis
of endometriosis.
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